These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Botulinum toxin B: a review of its therapeutic potential in the management of cervical dystonia. Figgitt DP; Noble S Drugs; 2002; 62(4):705-22. PubMed ID: 11893235 [TBL] [Abstract][Full Text] [Related]
5. Botulinum toxin for neurological disorders in a movement disorders clinic in Singapore. Tan AK Singapore Med J; 1998 Sep; 39(9):403-5. PubMed ID: 9885719 [TBL] [Abstract][Full Text] [Related]
6. [Botulinum toxin type B in the management of dystonia non-responsive to botulinum toxin type A]. Cardoso F Arq Neuropsiquiatr; 2003 Sep; 61(3A):607-10. PubMed ID: 14513166 [TBL] [Abstract][Full Text] [Related]
7. [Cost-utility analysis of two formulations of botulinum toxin type A in the treatment of blepharospasm and cervical dystonia in Spain]. Sanz-Granda A; Marti MJ; Catalan MJ Rev Neurol; 2018 Dec; 67(12):465-472. PubMed ID: 30536360 [TBL] [Abstract][Full Text] [Related]
8. Botulinum toxin type A versus botulinum toxin type B for cervical dystonia. Costa J; Borges A; Espírito-Santo C; Ferreira J; Coelho M; Moore P; Sampaio C Cochrane Database Syst Rev; 2005 Jan; (1):CD004314. PubMed ID: 15674940 [TBL] [Abstract][Full Text] [Related]
9. Patient considerations in the treatment of cervical dystonia: focus on botulinum toxin type A. Mills RR; Pagan FL Patient Prefer Adherence; 2015; 9():725-31. PubMed ID: 26082621 [TBL] [Abstract][Full Text] [Related]
10. [Treatment of focal dystonia with botulinum toxin A]. Sojer M; Wissel J; Müller J; Poewe W Wien Klin Wochenschr; 2001; 113 Suppl 4():6-10. PubMed ID: 15506045 [TBL] [Abstract][Full Text] [Related]
11. [A survey about the accessibility to botulinum toxin therapy for dystonia]. Mezaki T; Hayashi A; Nakase H; Hasegawa K No To Shinkei; 2006 Mar; 58(3):219-24. PubMed ID: 16629446 [TBL] [Abstract][Full Text] [Related]
12. The use of botulinum toxin type-B in the treatment of patients who have become unresponsive to botulinum toxin type-A -- initial experiences. Barnes MP; Best D; Kidd L; Roberts B; Stark S; Weeks P; Whitaker J Eur J Neurol; 2005 Dec; 12(12):947-55. PubMed ID: 16324088 [TBL] [Abstract][Full Text] [Related]
13. Botulinum toxin treatment in patients with focal dystonia and hemifacial spasm. A multicenter study of the Italian Movement Disorder Group. Berardelli A; Formica A; Mercuri B; Abbruzzese G; Agnoli A; Agostino R; Caraceni T; Carella F; De Fazio G; De Grandis D Ital J Neurol Sci; 1993 Jun; 14(5):361-7. PubMed ID: 8354632 [TBL] [Abstract][Full Text] [Related]
14. [Therapy of dystonia in Japan]. Mezaki T; Hayashi A; Nakase H; Hasegawa K Rinsho Shinkeigaku; 2005 Sep; 45(9):634-42. PubMed ID: 16248394 [TBL] [Abstract][Full Text] [Related]
15. Safety, effectiveness, and duration of effect of BOTOX after switching from Dysport for blepharospasm, cervical dystonia, and hemifacial spasm dystonia, and hemifacial spasm. Bihari K Curr Med Res Opin; 2005 Mar; 21(3):433-8. PubMed ID: 15811212 [TBL] [Abstract][Full Text] [Related]
16. Review of the FDA-approved uses of botulinum toxins, including data suggesting efficacy in pain reduction. Lew MF Clin J Pain; 2002; 18(6 Suppl):S142-6. PubMed ID: 12569961 [TBL] [Abstract][Full Text] [Related]